Dissecting the Dual Nature of Hyaluronan in the Tumor Microenvironment

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2019 May 29

PMID 31134064

Citations 80

Authors

Muhan Liu

Cornelia Tolg

Eva Turley

Affiliations

Soon will be listed here.

Abstract

Hyaluronan (HA) is a glycosaminoglycan with a simple structure but diverse and often opposing functions. The biological activities of this polysaccharide depend on its molecular weight and the identity of interacting receptors. HA is initially synthesized as high molecular-weight (HMW) polymers, which maintain homeostasis and restrain cell proliferation and migration in normal tissues. These HMW-HA functions are mediated by constitutively expressed receptors including CD44, LYVE-1, and STABILIN2. During normal processes such as tissue remodeling and wound healing, HMW-HA is fragmented into low molecular weight polymers (LMW-HA) by hyaluronidases and free radicals, which promote inflammation, immune cell recruitment and the epithelial cell migration. These functions are mediated by RHAMM and TLR2,4, which coordinate signaling with CD44 and other HA receptors. Tumor cells hijack the normally tightly regulated HA production/fragmentation associated with wound repair/remodeling, and these HA functions participate in driving and maintaining malignant progression. However, elevated HMW-HA production in the absence of fragmentation is linked to cancer resistance. The controlled production of HA polymer sizes and their functions are predicted to be key to dissecting the role of microenvironment in permitting or restraining the oncogenic potential of tissues. This review focuses on the dual nature of HA in cancer initiation vs. resistance, and the therapeutic potential of HA for chemo-prevention and as a target for cancer management.

Citing Articles

Increased HA/CD44/TGFβ signaling implicates in renal fibrosis of a Col4a5 mutant Alport mice.

Bao Y, Wu W, Lin J, Yang Y, Lin S, Su J Mol Med. 2025; 31(1):96.

PMID: 40075271 PMC: 11905560. DOI: 10.1186/s10020-025-01146-0.

Microbes, macrophages, and melanin: a unifying theory of disease as exemplified by cancer.

Berg S, Berg J Front Immunol. 2025; 15:1493978.

PMID: 39981299 PMC: 11840190. DOI: 10.3389/fimmu.2024.1493978.

Lutein derived from Xenostegia tridentata exhibits anticancer activities against A549 lung cancer cells via hyaluronidase inhibition.

Chatwichien J, Semakul N, Yimklan S, Suwanwong N, Naksing P, Ruchirawat S PLoS One. 2024; 19(12):e0315570.

PMID: 39680591 PMC: 11649105. DOI: 10.1371/journal.pone.0315570.

Identification of CD44 as a key engager to hyaluronic acid-rich extracellular matrices for cell traction force generation and tumor invasion in 3D.

Cheung B, Chen X, Davis H, Nordmann C, Toth J, Hodgson L Matrix Biol. 2024; 135():1-11.

PMID: 39528207 PMC: 11729355. DOI: 10.1016/j.matbio.2024.11.004.

Application of CAR-T cell therapy targeting mesothelin in solid tumor treatment.

Chen Q, Sun Y, Li H Discov Oncol. 2024; 15(1):289.

PMID: 39023820 PMC: 11258118. DOI: 10.1007/s12672-024-01159-x.

References

Itano N, Sawai T, Yoshida M, Lenas P, Yamada Y, Imagawa M . Three isoforms of mammalian hyaluronan synthases have distinct enzymatic properties. J Biol Chem. 1999; 274(35):25085-92. DOI: 10.1074/jbc.274.35.25085. View

Toida T, Ogita Y, Suzuki A, Toyoda H, Imanari T . Inhibition of hyaluronidase by fully O-sulfonated glycosaminoglycans. Arch Biochem Biophys. 1999; 370(2):176-82. DOI: 10.1006/abbi.1999.1395. View

Illmensee K, Mintz B . Totipotency and normal differentiation of single teratocarcinoma cells cloned by injection into blastocysts. Proc Natl Acad Sci U S A. 1976; 73(2):549-53. PMC: 335947. DOI: 10.1073/pnas.73.2.549. View

Hanahan D, Weinberg R . The hallmarks of cancer. Cell. 2000; 100(1):57-70. DOI: 10.1016/s0092-8674(00)81683-9. View

Pirinen R, Tammi R, Tammi M, Hirvikoski P, Parkkinen J, Johansson R . Prognostic value of hyaluronan expression in non-small-cell lung cancer: Increased stromal expression indicates unfavorable outcome in patients with adenocarcinoma. Int J Cancer. 2001; 95(1):12-7. DOI: 10.1002/1097-0215(20010120)95:1<12::aid-ijc1002>3.0.co;2-e. View

Lokeshwar V, Rubinowicz D, Schroeder G, Forgacs E, Minna J, Block N . Stromal and epithelial expression of tumor markers hyaluronic acid and HYAL1 hyaluronidase in prostate cancer. J Biol Chem. 2001; 276(15):11922-32. DOI: 10.1074/jbc.M008432200. View

Barcellos-Hoff M . It takes a tissue to make a tumor: epigenetics, cancer and the microenvironment. J Mammary Gland Biol Neoplasia. 2001; 6(2):213-21. DOI: 10.1023/a:1011317009329. View

Csoka A, Frost G, Stern R . The six hyaluronidase-like genes in the human and mouse genomes. Matrix Biol. 2001; 20(8):499-508. DOI: 10.1016/s0945-053x(01)00172-x. View

Sayo T, Sugiyama Y, Takahashi Y, Ozawa N, Sakai S, Ishikawa O . Hyaluronan synthase 3 regulates hyaluronan synthesis in cultured human keratinocytes. J Invest Dermatol. 2002; 118(1):43-8. DOI: 10.1046/j.0022-202x.2001.01613.x. View

10.

Enegd B, King J, Stylli S, Paradiso L, Kaye A, Novak U . Overexpression of hyaluronan synthase-2 reduces the tumorigenic potential of glioma cells lacking hyaluronidase activity. Neurosurgery. 2002; 50(6):1311-8. DOI: 10.1097/00006123-200206000-00023. View

11.

Wang F, Hansen R, Radisky D, Yoneda T, Barcellos-Hoff M, Petersen O . Phenotypic reversion or death of cancer cells by altering signaling pathways in three-dimensional contexts. J Natl Cancer Inst. 2002; 94(19):1494-503. PMC: 2975573. DOI: 10.1093/jnci/94.19.1494. View

12.

Franzmann E, Schroeder G, Goodwin W, Weed D, Fisher P, Lokeshwar V . Expression of tumor markers hyaluronic acid and hyaluronidase (HYAL1) in head and neck tumors. Int J Cancer. 2003; 106(3):438-45. DOI: 10.1002/ijc.11252. View

13.

Markovitz A, CIFONELLI J, DORFMAN A . The biosynthesis of hyaluronic acid by group A Streptococcus. VI. Biosynthesis from uridine nucleotides in cell-free extracts. J Biol Chem. 1959; 234:2343-50. View

14.

Liu N, Xu X, Chen J, Wang L, Yang S, Underhill C . Hyaluronan-binding peptide can inhibit tumor growth by interacting with Bcl-2. Int J Cancer. 2004; 109(1):49-57. DOI: 10.1002/ijc.11636. View

15.

Balazs E, HOGBERG B, Laurent T . The biological activity of hyaluron sulfuric acid. Acta Physiol Scand. 1951; 23(2-3):168-78. DOI: 10.1111/j.1748-1716.1951.tb00806.x. View

16.

Weaver V, Gilbert P . Watch thy neighbor: cancer is a communal affair. J Cell Sci. 2004; 117(Pt 8):1287-90. DOI: 10.1242/jcs.01137. View

17.

Kakizaki I, Kojima K, Takagaki K, Endo M, Kannagi R, Ito M . A novel mechanism for the inhibition of hyaluronan biosynthesis by 4-methylumbelliferone. J Biol Chem. 2004; 279(32):33281-9. DOI: 10.1074/jbc.M405918200. View

18.

Toole B . Hyaluronan: from extracellular glue to pericellular cue. Nat Rev Cancer. 2004; 4(7):528-39. DOI: 10.1038/nrc1391. View

19.

Del Fresno C, Otero K, Gomez-Garcia L, Gonzalez-Leon M, Soler-Ranger L, Fuentes-Prior P . Tumor cells deactivate human monocytes by up-regulating IL-1 receptor associated kinase-M expression via CD44 and TLR4. J Immunol. 2005; 174(5):3032-40. DOI: 10.4049/jimmunol.174.5.3032. View

20.

Mummert M . Immunologic roles of hyaluronan. Immunol Res. 2005; 31(3):189-206. DOI: 10.1385/IR:31:3:189. View